Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Vítor Macedo SilvaTiago Lima CapelaMarta FreitasTiago Cúrdia GonçalvesPedro Boal CarvalhoFrancisca Dias de CastroMaria João MoreiraJosé CotterPublished in: Inflammatory bowel diseases (2022)
IBD patients treated with immunomodulators, anti-tumor necrosis factor α agents and corticosteroids presented significantly lower anti-SARS-CoV-2 IgG levels following complete vaccination when compared with healthy control subjects. These findings support the benefit of additional booster injections in this population.